Literature DB >> 9800664

A rapid HPLC assay for voriconazole in human plasma.

R Gage1, D A Stopher.   

Abstract

This report describes a simple, rapid and reproducible method with a calibration range of 0.2-10 micrograms ml-1 voriconazole in human plasma which is more appropriate for routine clinical use than the authors previously published method. The method utilises protein precipitation with acetonitrile as the only sample preparation involved prior to reverse phase HPLC. No internal standard was required.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9800664     DOI: 10.1016/s0731-7085(98)00004-1

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  28 in total

1.  Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis.

Authors:  P Campoli; Q Al Abdallah; R Robitaille; N V Solis; J A Fielhaber; A S Kristof; M Laverdiere; S G Filler; D C Sheppard
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Authors:  Lorena Baietto; Antonio D'Avolio; Giusi Ventimiglia; Francesco Giuseppe De Rosa; Marco Siccardi; Marco Simiele; Mauro Sciandra; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

3.  Voriconazole and fluconazole increase the exposure to oral diazepam.

Authors:  Teijo I Saari; Kari Laine; Leif Bertilsson; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-08-04       Impact factor: 2.953

4.  Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

Authors:  Donna M MacCallum; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Topical voriconazole as a novel treatment for fungal keratitis.

Authors:  William Sponsel; Nancy Chen; Demi Dang; Gianmarco Paris; John Graybill; Laura K Najvar; Lei Zhou; Kwok-Wai Lam; Randolph Glickman; Frank Scribbick
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.

Authors:  Ville-Veikko Hynninen; Klaus T Olkkola; Kari Leino; Stefan Lundgren; Pertti J Neuvonen; Anders Rane; Mika Valtonen; Hanna Vyyryläinen; Kari Laine
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

7.  Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.

Authors:  Kathrin Kahle; Peter Langmann; Diana Schirmer; Ulrike Lenker; Daniela Keller; Annegret Helle; Hartwig Klinker; Werner J Heinz
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

8.  Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl.

Authors:  Teijo I Saari; Kari Laine; Mikko Neuvonen; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-11-07       Impact factor: 2.953

9.  Validated LC Method for the Estimation of Voriconazole in Bulk and Formulation.

Authors:  C N Patel; J B Dave; J V Patel; B Panigrahi
Journal:  Indian J Pharm Sci       Date:  2009-11       Impact factor: 0.975

10.  Development and Validation of Stability Indicating RP-HPLC Method for Voriconazole.

Authors:  A B Khetre; P K Sinha; Mrinalini C Damle; R Mehendre
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.